» Articles » PMID: 24132387

Pathological Fractures in Paediatric Patients with Inflammatory Bowel Disease

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 2013 Oct 18
PMID 24132387
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Paediatric inflammatory bowel disease (IBD), especially Crohn's disease (CD), is commonly associated with poor skeletal health, related to the direct effects of chronic inflammation, prolonged use of glucocorticoid (GC), poor nutrition, delayed puberty and low muscle mass. Low bone mineral density is commonly reported, although the prevalence of long bone fractures may not be increased in these patients. Emerging evidence however suggests that there may be an increased risk of vertebral fractures (VFs) in this group. VFs presenting at diagnosis of paediatric CD, prior to any GC exposure, have been reported, highlighting the deleterious effect of inflammation on skeletal health. This paper reviews the published literature on pathophysiology of skeletal morbidity and fractures in paediatric IBD, illustrated with a new case report of multiple VFs in a prepubertal girl with CD, soon after diagnosis, who received minimal amounts of oral GC. Optimising control of disease, addressing vitamin D deficiency, encouraging physical activity and ensuring normal growth and pubertal progression are paramount to management of bone health in these patients. Despite the lack of evidence, there may be a place for bisphosphonate treatment, especially in the presence of symptomatic pathological fractures, but this requires close monitoring by clinicians with expertise in paediatric bone health.

Conclusion: Chronic inflammation mediated by pro-inflammatory cytokines may have adverse effects on skeletal health in paediatric patients with IBD. The risk of vertebral fractures may be increased, even without exposure to glucocorticoid. Clinical monitoring of these patients requires careful attention to the various factors that impact on bone health.

Citing Articles

Diet, Sun, Physical Activity and Vitamin D Status in Children with Inflammatory Bowel Disease.

Sledzinska K, Landowski P, Zmijewski M, Kaminska B, Kowalski K, Liberek A Nutrients. 2022; 14(5).

PMID: 35268001 PMC: 8912613. DOI: 10.3390/nu14051029.


The Polygenic and Monogenic Basis of Paediatric Fractures.

Ghatan S, Costantini A, Li R, de Bruin C, Appelman-Dijkstra N, Winter E Curr Osteoporos Rep. 2021; 19(5):481-493.

PMID: 33945105 PMC: 8551106. DOI: 10.1007/s11914-021-00680-0.


Management of primary and secondary osteoporosis in children.

Sakka S, Cheung M Ther Adv Musculoskelet Dis. 2020; 12:1759720X20969262.

PMID: 33224280 PMC: 7649886. DOI: 10.1177/1759720X20969262.


Suppressor of cytokine signaling 2 () deletion protects bone health of mice with DSS-induced inflammatory bowel disease.

Dobie R, Macrae V, Pass C, Milne E, Ahmed S, Farquharson C Dis Model Mech. 2018; 11(1).

PMID: 29343614 PMC: 5818069. DOI: 10.1242/dmm.028456.


Musculoskeletal system in children and adolescents with inflammatory bowel disease: normal muscle force, decreased trabecular bone mineral density and low prevalence of vertebral fractures.

Maratova K, Hradsky O, Matyskova J, Copova I, Soucek O, Sumnik Z Eur J Pediatr. 2017; 176(10):1355-1363.

PMID: 28840427 DOI: 10.1007/s00431-017-2988-7.


References
1.
Tuchman S, Thayu M, Shults J, Zemel B, Burnham J, Leonard M . Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr. 2008; 153(4):484-90. PMC: 2683408. DOI: 10.1016/j.jpeds.2008.04.028. View

2.
Baim S, Leonard M, Bianchi M, Hans D, Kalkwarf H, Langman C . Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008; 11(1):6-21. DOI: 10.1016/j.jocd.2007.12.002. View

3.
Beattie R, Camacho-Hubner C, Wacharasindhu S, Cotterill A, Walker-Smith J, Savage M . Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf). 1999; 49(4):483-9. DOI: 10.1046/j.1365-2265.1998.00562.x. View

4.
Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F . Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13(4):416-23. DOI: 10.1002/ibd.20039. View

5.
Liu X, Kirschenbaum A, Yao S, Levine A . Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2004; 146(4):1991-8. DOI: 10.1210/en.2004-1167. View